Palliation of nausea and vomiting

CME Cancer Medicine

Volumn 1, Issue 1, 2002, Pages 18-22

  Mannix, Kathryn A ^a  

^a Marie Curie Centre   (United Kingdom)

Author keywords

Anti emetics; Drug treatment; Nausea; Palliative care; Vomiting

Indexed keywords

ANTIEMETIC AGENT; ATROPINE; CANNABINOID; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; CORTICOSTEROID DERIVATIVE; CYCLIZINE; DIPHENHYDRAMINE; DOMPERIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GLYCOPYRRONIUM BROMIDE; GRANISETRON; HALOPERIDOL; HISTAMINE H1 RECEPTOR ANTAGONIST; LEVOMEPROMAZINE; METOCLOPRAMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; OCTREOTIDE; ONDANSETRON; PHENOTHIAZINE DERIVATIVE; SCOPOLAMINE BROMIDE; SEROTONIN 2 ANTAGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SOMATOSTATIN DERIVATIVE; TROPISETRON; UNINDEXED DRUG;

ANIMAL MODEL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HUMAN; HYPOTENSION; INTESTINE OBSTRUCTION; LIVER METASTASIS; LOW DRUG DOSE; MEDICAL PRACTICE; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; ORTHOSTATIC HYPERTENSION; PALLIATIVE THERAPY; PRESCRIPTION; REVIEW; SEDATION; SIDE EFFECT; STOMACH EMPTYING; STOMACH FUNCTION DISORDER; URINE RETENTION; XEROSTOMIA;

EID: 0036937249     PISSN: 14758075     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Coates A, et al; On the receiving end - Patient perception of the side-effects of cancer chemotherapy. European Journal of Cancer 1983; 19: 203-8.
2. Dunlop GM. A study of the relative frequency and importance of gastrointestinal symptoms, and weakness in patients with far advanced cancer. Palliative Medicine 1989; 4: 37-43.
3. Fainsinger R, Miller M, Bruera E, et al; Symptom control during the last week of life on a palliative care unit. Journal of Palliative Care 1991; 7: 5-11.
4. Bliss JM, Robertson B, Selby PJ. The impact of nausea and vomiting upon quality of life measures. British Journal of Cancer 1992; 66: S14-23.
5. Gron S, Zech S, Diefenbach C, et al; Prevalence and pattern of symptoms in patients with cancer pain: A prospective evaluation of 1635 cancer patient referred to a pain clinic. Journal of Pain and Symptom Management 1994; 9: 372-82.
6. Borison HL, Wang SC. Physiology and pharmacology of vomiting. Pharmacological Reviews 1953; 5: 192-230.
7. Wang SC. Emetic and anti-emetic drugs. In: Roots WS, Hofman FG, eds. Physiological Pharmacology: A Comprehensive Treatise. Vol. II. New York: Academic Press, 1965: 255-328.
8. Grundberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. New England Journal of Medicine 1993; 329: 1790-6.
9. Davis CJ, Harding RK, Leslie RA, et al; The organisation of vomiting as a protective reflex. In: Davis CJ, Lake-Bakaar GV, Grahme-Smith DG, eds. Nausea and Vomiting: Mechanisms and Treatment. Berlin: Springer-Verlag, 1986: 65-75.
10. Willems JL, Lefebvre RA. Peripheral nervous pathways involved in nausea and vomiting. In: Davis CJ, Lake-Bakaar GV, Grahame-Smith DG, eds. Nausea and Vomiting: Mechanisms and Treatment. Berlin: Springer-Verlag, 1986: 56-64.
11. Naylor R, Rudd JA. Emesis and anti-emesis. In: GW Hanks (ed). Cancer Surveys, Vol. 21. Palliative Medicine: Problem Areas in Pain and Symptom Management. New York: Cold Spring Harbor Laboratory Press, 1994: 117-135.
12. Soukop M, Cunningham D. The treatment of nausea and vomiting induced by cytotoxic drugs. Ballières Clinical Oncology 1987; 1: 307-26.
13. Peroutka SJ, Snyder SH. Anti-emetics: Neurotransmitter binding predicts therapeutic actions. Lancet 1982; ii: 658-9.
14. Ison PJ, Peroutka SJ. Neurotransmitter receptor binding studies predict antiemetic efficacy and side effects. Cancer Treatment Reports 1986; 70: 637-41.
15. 3 antagonists: Recent advances. In: Ellis GP, Luscombe DK, eds. Progress in Medicinal Chemistry Vol. 29. Elsevier Science Publishers, 1992.
16. Harris AL, Cantwell BMJ. Mechanisms and treatment of cytotoxic-induced nausea and vomiting. In: Davis CJ, Lake-Bakaar GC, Grahame-Smith DG, eds. Nausea and Vomiting: Mechanisms and Treatment. Berlin: Springer-Verlag, 1986: 78-93.
17. Chlopromazine (hydrochloride). In: Dollery C, ed. Therapeutic Drugs, Vol. 1, Edinburgh: Churchill Livingstone, 1991; 6: C201-6.
18. Diphenhydramine. In: Dollery C, ed. Therapeutic Drugs, Vol. 1, Edinburgh: Churchill Livingstone, 1991: D164-8.
19. Stott JRR. Mechanisms and treatment of motion illness. In: CJ Davis, CV Lake-Bakaar, DG Grahame-Smith, eds. Nausea and Vomiting: Mechanisms and Treatment. Berlin: Springer-Verlag, 1986.
20. DeConno F, Caraceni A, Zecca E, et al; Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. Journal of Pain and Symptom Management 1991; 6: 484-6.
21. Mirakhur RK, Dundee JW. Glyopyrrolate: Pharmacology and clinical use. Anaesthesia 1983; 38: 1195-204.
22. Kris MG, Baltzer L, Pisters KMW, et al; Enhancing the effectiveness of the specific serotonin antagonists. Cancer 1993; 72: 3436-42.
23. 3 receptor antagonists the same? European Journal of Cancer 1992; 28A: S2-6.
24. 3 receptor research. European Journal of Pharmacology and Molecular Pharmacology 1990; 88: 301-12.
25. Twycross R, Barkby GD, Hallwood PM. The use of low-dose levomepromazine (methotrimeprazine) in the management of nausea and vomiting. Progress in Palliative Care 1997; 5: 49-53.
26. 4 receptor: Naughty but nice. Trends in Pharmacological Science 1989; 10: 385-6.
27. Cassileth PA, Lusk GJ, Torn S, et al; Anti-emetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy. Archives of Internal Medicine 1983; 143: 1347-9.
28. Aapro MS. Present role of corticosteroids as anti-emetics. In: Recent Results in Cancer Research Vol 121. Berlin: Springer-Verlag, 1991: 91-100.
29. Doblin RE, Kleiman MAR. Marijuana as anti-emetic medicine: A survey of oncologists' experiences and attitudes. Journal of Clinical Oncology 1991; 9: 1314-19.
30. Gordon P, Comi RJ, Maton PN, et al; Somatostatin and somatostatin anologue (SMS 201-995) in treatment of hormone-secreting tumours of the pituitary and gastro-intestinal tract and non-neoplastic disease of the gut. Annals of Internal Medicine 1989; 110: 35-50.
31. Fallon MT. The physiology of somatostatin and its synthetic analogue, octreotide. European Journal of Palliative Care 1994; 1: 20-22.
32. Lichter I. Results of anti-emetic management in terminal illness. Journal of Palliative Care 1993; 9: 19-21.
33. Twycross R & Back I. Nausea and vomiting in advanced cancer. European Journal of Palliative Care 1985; 5: 39-45.
34. Bains MJ, Oliver DJ, Carter RL. Medical management of intestinal obstruction in patients with advanced malignant disease: A clinical and pathological study. Lancet 1985; ii 990-993.
35. Mercadante S, Maddaloni S. Octreotide in the management of inoperable gastrointestinal obstruction in terminal cancer patients. Journal of Pain and Symptom Management 1992; 7: 496-8.
36. Mercadante S, Spoldi E, Caracerii A, et al; Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliative Medicine 1993; 7: 295-9.
37. Riley J, Fallon MT. Octreotide in terminal malignant obstruction of the gastrointestinal tract. European Journal of Palliative Care 1994; 1: 23-5.